SAN DIEGO, CA --(Marketwired - November 03, 2016) - Medical Marijuana, Inc. (
The Company's product pipeline chart shows what stage of clinical trials each drug of AXIM® Biotech is in, the indication the drug is intended to treat and the expected date to receive an NDA from the U.S. Food and Drug Administration (FDA) and/ or European Medicines Agency (EMA). The chart also shows the anticipated market introduction date of the Company's various functional food and nutraceutical products.
"We commend AXIM for publishing a product pipeline chart on its website as it provides potential patients and investors with critical Company information about the numerous cannabinoid-based therapeutic products that AXIM currently has undergoing clinical trials and when those products are anticipated to be on the market and approved by the FDA and EMA," said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. "It's exciting to see the actual timelines for these cannabinoid-based innovations currently in development, as we're confident that once on the market these novel therapeutics will provide consumers with a wide variety of new options worldwide."
View the product pipeline chart here.
An AXIM® Biotech breakthrough invention on pace to be fully registered by the EMA and FDA as soon as 2019 is the world's first patented cannabinoid controlled-release chewing gum: MedChew Rx™. Recently featured by Reuters global news agency, MedChew Rx™ will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for multiple sclerosis (MS) in the Reuters article, the potential economic impact for MedChew Rx™ is estimated at $4.8 billion USD - for spasticity and pain associated with MS.
AXIM's pipeline of intellectual property (IP) protected cannabinoid-based products include:
- MedChew Rx™ - THC/CBD cannabinoid controlled-release functional chewing gum to address pain and muscle spasticity in multiple sclerosis (MS) patients as well as numerous indication extensions based on the proprietary delivery platform
- RENECANN™ - the world's first cannabigerol (CBG)-based skincare product line
- ORAXIMAX™ - the world's first CBG-based oral care product line
- Suppocann™ - a suppository cannabinoid-release product for GI conditions such as IBD, IBS and Crohn's disease
- Ophthocann™ and Cannbleph™ - cannabinoid-based products for reduction of intraocular pressure and for relief of conjunctivitis
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com .
To see Medical Marijuana, Inc.'s video statement, click here . Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
About AXIM ®
AXIM® Biotechnologies, Inc. (
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Contact information Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829- 0070 andrew.hard@cmwmedia.com www.cmwmedia.com Corporate Business Contact: Nicholas R. Massalas Director of Business Development Medical Marijuana, Inc. OTC Symbol: MJNA Toll Free: 888-OTC- MJNA (888-682- 6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc Investor Relations Contact: EquiNet, LLC Toll Free: (877) 964.6463 Office/Direct: (858) 264-6500 Email: info@equinet.us www.equinet.us
